Caris Life Sciences
launched Caris Detect and introduced AI-powered molecular insights for NSCLC patients, alongside AI models predicting brain-metastases risk in breast and lung cancer, its Caris ChromoSeq assay, and its Caris Assure blood-based test.
- Country
- United States
- Ticker
- CAI
Commercial
Caris Detect / Caris Assure / ChromoSeq
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Multi-omics diagnostic panels for precision oncology | diagnostics-medtech | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.